SIX · DOCM.SW
DocMorris AG
CHF 16.03-CHF 0.05 (-0.31%)
DocMorris AG’s quoted price sits in the upper half of its reported 52-week range, 3.32% below the high.
Loading market information…
SIX · SANN.SW · CHF
Stock price, earnings
Quote as of Oct 29, 2026, 04:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CHF. Historical prices are not a forecast.
Santhera Pharmaceuticals Holding AG’s quoted price sits in the upper half of its reported 52-week range, 17.2% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Santhera Pharmaceuticals Holding AG’s next earnings report is currently expected on Apr 29, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Santhera Pharmaceuticals Holding AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Latest available per-share figures in CHF. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:37 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| CHF 14.10M+151.79% vs estimate |
| Q4 2023 | Apr 25, 2024 | CHF 7.00 | -CHF 200.00K-102.41% vs estimate |
|---|
| Q2 2023 | Sep 7, 2023 | -CHF 2.09 | CHF 3.94M |
|---|
| Q4 2022 | Apr 27, 2023 | -CHF 6.43-8,137.5% vs estimate | CHF 295.00K-96.65% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CHF 16.03-CHF 0.05 (-0.31%)
DocMorris AG’s quoted price sits in the upper half of its reported 52-week range, 3.32% below the high.
CHF 48.60+CHF 0.40 (+0.83%)
COLTENE Holding AG’s quoted price sits in the lower half of its reported 52-week range, 17.63% below the high.
CHF 5.80+CHF 0.01 (+0.17%)
Ascom Holding AG’s quoted price sits in the upper half of its reported 52-week range, 14.71% below the high.
CHF 9.13+CHF 0.29 (+3.28%)
Newron Pharmaceuticals S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 71.33% below the high.
CHF 2.99-CHF 0.01 (-0.33%)
Molecular Partners AG’s quoted price sits in the lower half of its reported 52-week range, 24.49% below the high.
CHF 1.07CHF 0.00 (0.0%)
SHL Telemedicine Ltd.’s quoted price sits in the upper half of its reported 52-week range, 28.19% below the high.
CHF 2.89+CHF 0.03 (+0.87%)
Relief Therapeutics Holding AG’s quoted price sits in the lower half of its reported 52-week range, 37.15% below the high.
CHF 2.25-CHF 0.02 (-0.88%)
EvoNext Holdings S.A.’s quoted price sits in the upper half of its reported 52-week range, 17.88% below the high.
